A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Inclusion Criteria:

1. Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation
2. No prior chemotherapy or any other systemic therapy for metastatic NSCLC
3. Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, if progression has occurred >12 months from end of last therapy
4. Known tumor PD-L1 status
5. Tumors that lack activating EGFR mutations and ALK fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care
6. WHO/ECOG status at 0 or 1 at enrollment
7. Life expectancy of at least 12 weeks
8. Troponin I or T ≤ ULN (per institutional guidelines)

Exclusion Criteria:

1. Active or prior documented autoimmune or inflammatory disorders
2. History of active primary immunodeficiency
3. Any prior chemotherapy or any other systemic therapy for metastatic NSCLC
4. Untreated CNS metastases